Company news

Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) news

Every Dr. Reddy's Laboratories Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Dr. Reddy's Laboratories Ltd. stock analysis →

Press releases & updates

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose ...

August 4, 2026

Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026

August 1, 2026

Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026

July 22, 2026

Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026

July 13, 2026

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

June 29, 2026

Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

June 26, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

June 13, 2026

Dr Reddy Laboratories : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)

May 29, 2026

Press Release May 28 2026

May 28, 2026

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

May 16, 2026

Press Release May 16 2026

May 15, 2026

Press Release May 12 2026

May 12, 2026

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

April 29, 2026

Press Release Apr 24 2026

April 24, 2026

Press Release Mar 21 2026

March 21, 2026

Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

February 20, 2026

Press Release Feb 18 2026

February 18, 2026

Coya Therapeutics Announces $11.1 Million Private Placement

January 30, 2026

Press Release Jan 14 2026

January 14, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent...

January 14, 2026

Press Release Jan 08 2026

January 8, 2026

Press Release Dec 12 2025

December 12, 2025

Dr. Reddy's Laboratories Ltd. Press Release Dec 12 2025

December 11, 2025

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

December 9, 2025

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

December 8, 2025

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhi...

December 2, 2025

Press Release Nov 24 2025

November 24, 2025

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

November 12, 2025

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 6, 2025

Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025

October 22, 2025

Press Release Oct 13 2025

October 13, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic a...

October 3, 2025

Press Release Sep 16 2025

September 16, 2025

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic La...

August 25, 2025

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

August 18, 2025

Press Release Jul 23 2025

July 23, 2025

Dr. Reddy’s Q1FY26 Financial Results

July 23, 2025

Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan

July 21, 2025

Press Release Jul 15 2025

July 15, 2025

Press Release Jun 05 2025

June 5, 2025

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 5, 2025

Dr. Reddy's Laboratories Ltd. Press Release Jun 05 2025

June 4, 2025

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

May 9, 2025

Press Release Apr 24 2025

April 24, 2025

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 18, 2025

Press Release Mar 13 2025

March 13, 2025

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeli...

March 13, 2025

Press Release Nov 28 2024

November 28, 2024

Dr. Reddy's Laboratories Ltd. Press Release Nov 28 2024

November 27, 2024

Press Release Oct 28 2024

October 28, 2024

Older →